Business ❯ Pharmaceuticals

Drug Development

Clinical Trials Weight Loss Drugs Obesity Treatments Market Competition Licensing Agreements Market Trends Clinical Research Oncology Obesity Drugs Market Access

Lilly and Insilico Strike $2.75 Billion AI Drug Discovery Pact

Lilly gains exclusive rights to Insilico's AI-designed drug candidates to accelerate drug discovery.

Summit Therapeutics Shares Rally as Ivonescimab Trials Near Q2 Readout

Pfizer, Valneva Seek Approval for Lyme Vaccine After >70% Efficacy in Phase 3

Corcept Faces Securities Class Action Over Relacorilant Disclosures as Firms Rally Investors Before April 21 Deadline

Roche Expands NVIDIA Partnership, Building Pharma’s Largest Hybrid‑Cloud AI Factory

HSBC Cuts Eli Lilly to Reduce, Lowers Target to $850 on GLP-1 Reset

Roche Launches Nvidia-Powered AI Factory With 2,176 New Blackwell GPUs, Claims Pharma’s Largest Footprint

Vertex’s IgA Nephropathy Drug Hits Phase 3 Goals, FDA Filing Slated for March

Novo Nordisk Licenses Vivtex Platform in $2.1 Billion Push for Oral Obesity and Diabetes Drugs

Novo’s CagriSema Falls Short of Lilly’s Tirzepatide in 84-Week Head‑to‑Head Trial

Astellas–Vir Prostate Cancer Alliance Launches With New Data as VIR Stock Surges

Novo Nordisk Plunges After Obesity Drug Cagrisema Misses Phase-3 Goal

Lilly’s Taltz Plus Zepbound Outperforms Taltz Alone in Phase 3b Psoriasis-Obesity Trial

Novo Nordisk Slumps on Weak 2026 Outlook as GLP-1 Pill Uptake Builds

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

Eli Lilly Builds $1.5 Billion Stockpile of Orforglipron as FDA Decision Nears

Sanofi Replaces Paul Hudson, Names Belén Garijo as Next CEO

Eli Lilly Tightens GLP-1 Grip, Guides Up to $83 Billion for 2026

Takeda Strikes Multi-Year AI Drug Discovery Pact With Iambic Worth Over $1.7 Billion

Lilly and Innovent Forge Territory-Split Cancer and Immunology Alliance